Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. CS (NQ: MRUS )

45.69 +1.34 (+3.02%)
Streaming Delayed Price Updated: 3:42 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 450,227
Open 44.73
Bid (Size) 45.65 (1)
Ask (Size) 45.70 (2)
Prev. Close 44.35
Today's Range 44.17 - 47.05
52wk Range 22.26 - 61.61
Shares Outstanding 46,530,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire

Performance

YTD
+59.64%
+59.64%
1 Month
-14.10%
-14.10%
3 Month
-14.36%
-14.36%
6 Month
+3.68%
+3.68%
1 Year
+93.27%
+93.27%

More News

Read More
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
From Merus N.V.
Via GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
From Merus N.V.
Via GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
Via Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
Via Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.